A generic version of a drug that’s “as close as we’ve ever been to an HIV vaccine” could be made for $40 a year per patient (with a 30% profit). Current pricing by Gilead: $42,250 per year.
Advertise here with Carbon Ads
This site is made possible by member support. 💞
Big thanks to Arcustech for hosting the site and offering amazing tech support.
When you buy through links on kottke.org, I may earn an affiliate commission. Thanks for supporting the site!
kottke.org. home of fine hypertext products since 1998.
Beloved by 86.47% of the web.
Comments 2
If I recall correctly, Gilead had nothing to do with the development of this drug and simply bought the patent. They are cartoon villains and we are long overdue for a more affordable solution.
I'm tempted to ask how people sleep at night, knowing that they chose massive profits over saving lives. But I realize the answer is that they sleep just fine. If they can't summon the basic humanity to make this drug affordable to all who need it, then someone needs to make that decision for them
If you feel like this comment goes against the grain of the community guidelines or is otherwise inappropriate, please let me know and I will take a look at it.
This thread is closed for new comments & replies. Thanks to everyone for participating!